Currently, the oral PDE4 inhibitor Roflumilast has been approved for use in a subset of patients with severe COPD and history of exacerbation episodes [5] on top of standard of care, which includes inhaled long-acting β2-agonist, muscarinic antagonist, and corticosteroids. This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.